N. Cabrera

发表

Inhibitor development after switching of FVIII concentrate in multitransfused patients with severe haemophilia A

J. Aznar, A. Moret, F. Ibáñez, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Diagnosis and management of von willebrand disease in Spain

V. Jiménez‐Yuste, J. Mateo, J. Batlle, 2018 .

Inhibitors in haemophilia A: current management and open issues

A. Cid, J. Aznar, A. Moret, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

One‐stage and chromogenic FVIII:C assay discrepancy in mild haemophilia A and the relationship with the mutation and bleeding phenotype

A. Cid, J. Aznar, A. Moret, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

Inhibitor development in one patient and laboratory discrepancies in several families with both mild haemophilia and Arg531Cys mutation

A. Cid, J. Aznar, N. Cabrera, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

Role of multimeric analysis of von Willebrand factor (VWF) in von Willebrand disease (VWD) diagnosis: Lessons from the PCM-EVW-ES Spanish project

V. Jiménez‐Yuste, J. Mateo, J. Batlle, 2018, PloS one.

Founder haplotype associated with the factor VIII Asp1241Glu polymorphism in a cohort of mild hemophilia A patients

F. Martínez, A. Cid, J. Aznar, 2008, Journal of thrombosis and haemostasis : JTH.

A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine®, a high‐purity factor IX concentrate, in patients with severe haemophilia B

T. Lissitchkov, J. Aznar, N. Cabrera, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Pharmacokinetic study of a high‐purity factor IX concentrate (Factor IX Grifols®) with a 6‐month follow up in previously treated patients with severe haemophilia B

T. Lissitchkov, J. Aznar, N. Cabrera, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Molecular and clinical profile of von Willebrand disease in Spain (PCM–EVW–ES): Proposal for a new diagnostic paradigm

V. Jiménez‐Yuste, J. Mateo, J. Batlle, 2015, Thrombosis and Haemostasis.

Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): comprehensive genetic analysis by next-generation sequencing of 480 patients

V. Jiménez‐Yuste, J. Mateo, J. Batlle, 2017, Haematologica.

Comparison of a new chemiluminescent immunoassay for von Willebrand factor activity with the ristocetin cofactor‐induced platelet agglutination method

F. España, A. Cid, J. Aznar, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

First application of MLPA method in severe von Willebrand disease. Confirmation of a new large VWF gene deletion and identification of heterozygous carriers

A. Cid, J. Aznar, A. Moret, 2011, British journal of haematology.

Von Willebrand's disease: a novel mutation, P1824H and the incidence of R1205H defect among families with dominant quantitative von Willebrand factor deficiency.

A. Cid, J. Aznar, N. Cabrera, 2006, Haematologica.

Unraveling the Influence of Common von Willebrand factor variants on von Willebrand Disease Phenotype: An Exploratory Study on the Molecular and Clinical Profile of von Willebrand Disease in Spain Cohort

V. Jiménez‐Yuste, J. Mateo, J. Batlle, 2020, Thrombosis and Haemostasis.

Unraveling the effect of silent, intronic and missense mutations on VWF splicing: contribution of next generation sequencing in the study of mRNA

V. Jiménez‐Yuste, J. Mateo, J. Batlle, 2018, Haematologica.

Severe and moderate hemophilia A: identification of 38 new genetic alterations

A. Cid, J. Aznar, N. Cabrera, 2008, Haematologica.

Treatment in a haemophiliac A patient with paroxysmal atrial fibrillation and ischemic heart disease

A. Cid, N. Cabrera, S. Haya, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.